Fetomaternal hemorrhage among pregnant women in Accra, Ghana

Akorsu, Elliot E.; Acquaye, Joseph; Benneh, Amma A.; Oppong, Samuel A.; Olayemi, Edeghonghon

doi:10.1002/ijgo.12890

Cited by 5 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These antibodies pass through the placenta and cause the destruction of fetal RBCs ( Troia et al, 2019 ; Hookins and Vatsayan, 2020 ; Monteiro et al, 2021 ). 16 weeks is the earliest placenta rupture, so pregnant women at 16 weeks are at risk for FMH ( Akorsu et al, 2019 ; Athiel et al, 2020 ). David M conducts the Kleihauer–Betke test (K–B test) and concludes that 22.5% of Rh D-negative pregnant women carry Rh D-positive fetuses, resulting in FMH ( David et al, 2004 ).…”

Section: Introductionmentioning

confidence: 99%

Prenatal diagnosis of fetomaternal hemorrhage by a novel hydrogel fluoroimmunoassay that accurately quantifies fetal haemoglobin

Yin

Wang

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Objective: Fetomaternal hemorrhage (FMH) is an alloimmunization resulting caused by the incompatibility between fetal and maternal blood. For the prevention of newborn haemolytic disease (HDN), it is crucial to quantify the amount of fetomaternal hemorrhage. However, the classical Kleihauer–Betke test (K-B test) for detecting fetomaternal hemorrhage is limited by experimental tools and conditions and is not suitable for routine clinical use. Consequently, the method of prenatal diagnosis of fetomaternal hemorrhage applicable to the clinic is a topic worthy of further study. Therefore, it is worthwhile to further investigation on the clinically applicable prenatal diagnosis method for fetomaternal hemorrhage.Methods: This experiment demonstrates hydrogel’s ability to separate sensitized red blood cells from soluble antibodies. Using flow cytometry the fluorescence values of sensitized red blood cells and fluorophore-labeled antibodies were measured, and the testing steps for the detection products of a novel technology were determined. The properties of a hydrogel fluoroimmunoassay were evaluated by distinguishing between the amounts of fetal and adult haemoglobin. The precision of this technology is evaluated using the Kleihauer–Betke test as a comparison.Results: This experiment compared the detection of haemoglobin fluorescence in adults (n = 2) and fetuses (n = 6). At the same time, the fluorescence intensity of different fetal haemoglobin (HbF) in adult haemoglobin (HbA) was calculated. The fluorescence value is 1.6% when the fetal hemoglobin concentration is 0.1%.Conclusion: The novel hydrogel fluoroimmunoassay can accurately determine the fluorescence intensity by flow cytometry to differentiate fetal haemoglobin from adult haemoglobin, quantitatively prenatally diagnose fetal haemoglobin, address the incompatibility between fetal and maternal blood types, and prevent alloimmunization.

show abstract

Section: Introductionmentioning

confidence: 99%

Prenatal diagnosis of fetomaternal hemorrhage by a novel hydrogel fluoroimmunoassay that accurately quantifies fetal haemoglobin

Yin

Wang

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…In addition, if the fetus survives during pregnancy, mothers with incompatible blood types can produce specific IgG antibodies against fetal red blood cells, which can cause hemolysis in fetal red blood cells via the placenta. Nonetheless, if the fetus survives, the newborn may still develop hemolytic disease or pass away after a few months ( Akorsu et al, 2019 ; Song et al, 2021 ). Common antibodies that can easily cause fetal bleeding include anti-A, anti-B, anti-D, anti-Kell, anti-E, and anti-C antibodies ( Pal and Williams, 2015 ; Erhabor et al, 2020 ; Minuk et al, 2020 ; Tneh et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

A novel enzyme-linked immunostaining technique based on silk membrane for the prenatal detection of fetomaternal haemorrhage

Li,

Duan

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Objective: Developing a simple, rapid, reliable, sensitive, and cost-effective method for prenatal detection of fetomaternal haemorrhage by combining multi-aperture silk membrane with enzyme-linked immunosorbent assay (ELISA), which does not require any complicated instruments and can be visually colored, so as to provide a new method for clinical detection of fetomaternal haemorrhage.Methods: As a carrier, a chemically treated silk membrane was used to immobilize anti-A/anti-B antibody reagent. PBS washed slowly after vertically dropping red blood cells. After adding biotin-labeled anti-A/anti-B antibody reagent, PBS is slowly washed, enzyme-labeled avidin is added, and TMB is used for color development after washing.Results: When there were both anti-A and anti-B fetal erythrocytes in pregnant women’s peripheral blood, the final color was dark brown. When there are no anti-A and anti-B fetal red blood cells in pregnant women’s peripheral blood, the final color development results do not change, which corresponds to the color of chemically treated silk membrane.Conclusion: The new enzyme-linked immunosorbent assay (ELISA) based on a silk membrane can distinguish fetal red blood cells from maternal red blood cells prenatally and can be used for prenatal detection of fetomaternal haemorrhage.

show abstract

“…Prior history of HDN or hydrops fetalis, chorionic villus sampling, amniocentesis, antepartum hemorrhage, miscarriages, abortions, and maternal blood transfusions are all risk factors for FMH. 18 Blood testing throughout the first trimester is very important. Pregnant women with blood type O should be closely examined during and after birth.…”

mentioning

confidence: 99%

Hemolytic Disease of the Newborn: A Review of Current Trends and Prospects

Myle¹,

Al-Khattabi

2021

PHMT

View full text Add to dashboard Cite

Hemolytic disease of the newborn (HDN), also known as Erythroblastosis fetalis, is a hemolytic condition that predominantly affects rhesus-positive fetuses and infants born to rhesus-negative mothers. The pathophysiology of HDN begins with maternal antibodies attacking fetal red blood cells following alloimmunization due to rhesus or ABO incompatibility between the maternal and fetal blood. Previously, HDN was known to cause fetal death in 1% of all pregnancies, but with the advent of immunoprophylactic therapies, the condition can be currently fairly well managed with fewer complications if diagnosed early. Diagnosis calls for extensive history taking, physical examination, serological studies, and imaging modalities such as pelvic ultrasound scans. To prevent the disease, earlier intravenous immunoglobulin (IVIG) should be given to pregnant Rh-women who have not been sensitized. It is also vital to understand prospective complications such as severe hyperbilirubinemia and develop appropriate remedies. Because of its great incidence and nature, HDN has been thoroughly explored, and more studies are being conducted each year, revealing new insights about the condition. This review covers the disorder's etiology, diagnosis, and management, including the most current findings as of 2021, as well as trends and prospects, to help in future research and evidence-based medical practice.

show abstract

Fetomaternal hemorrhage among pregnant women in Accra, Ghana

Cited by 5 publications

References 15 publications

Prenatal diagnosis of fetomaternal hemorrhage by a novel hydrogel fluoroimmunoassay that accurately quantifies fetal haemoglobin

Prenatal diagnosis of fetomaternal hemorrhage by a novel hydrogel fluoroimmunoassay that accurately quantifies fetal haemoglobin

A novel enzyme-linked immunostaining technique based on silk membrane for the prenatal detection of fetomaternal haemorrhage

Hemolytic Disease of the Newborn: A Review of Current Trends and Prospects

Contact Info

Product

Resources

About